---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic impact of diagnostic testing"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic impact of diagnostic testing. Topics: Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy; Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer; Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer; Costs of FIB-4 followed by VCTE or ELF screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis; 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy

> “Patient has stage F2 or F3 fibrosis prior to initiating treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required] identified by ONE of the following (a, b, c, or d):”
> “Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Magnetic resonance elastography (MRE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Enhanced Liver Fibrosis™ (ELF) test performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required] with a score of ≥ 9.2 to ≤ 10.5 [documentation required]”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

<a id="topic-2.2.1.8.4-2"></a>

### Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer

> “Hepatology workup costs comprised of specialist consultation and fibrosis staging, which reflected standard practice using a combination of liver biopsy, ELF, and imaging-based modalities (TE, MRE, or liver ultrasound). Resource use frequencies for each staging component were estimated from the same real-world cohort and are reported in Table 2.”
> “All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

| Test or service, 2025 USD | Cost | Resource use in hepatology workup |
| --- | --- | --- |
| ELF test, one-time screening cost (range) | “200” (“170–230”) | Not applicable |
| FIB-4 test, one-time screening cost | “0” | Not applicable |
| Hepatology consultation | “257” | “100” |
| ELF test in hepatology workup | “185” | “25” |
| Transient elastography | “32” | “25” |
| Ultrasound liver | “136” | “200” |
| MRI or CT abdomen or liver | “323” | “5” |
| Liver biopsy | “354” | “15” |

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.4-3"></a>

### Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer

> “We developed a decision-analytic model for MASLD natural history and treatment to compare 6 noninvasive test strategies using Fibrosis-4 (FIB-4) and/or enhanced liver fibrosis (ELF) tests at varying cutoffs. Patients identified with significant fibrosis were referred for hepatology staging (biopsy and/or imaging-based), and eligible individuals were considered for Resmetirom ($47,400/y; mean duration: 1.6–1.8 year).”
> “Sequential screening with ELF (cutoff 9.80) following indeterminate FIB-4 (1.3–2.67) was the most cost-effective, yielding 8.610 QALYs and $96,990 in lifetime costs at a $100,000/QALY threshold. ELF-alone screening at a 9.00 cutoff maximized QALYs and individuals treated but increased unnecessary referrals.”
> “Resmetirom treatment costs were obtained from Centers for Medicare & Medicaid Services ($47,400/y at the time of analysis) and applied exclusively to individuals with F2-3 fibrosis.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.4-4"></a>

### Costs of FIB-4 followed by VCTE or ELF screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis

> “Six screening strategies were assessed, using either vibration-controlled transient elastography (VCTE) or the enhanced liver fibrosis (ELF) test as a second-line test following an initial Fibrosis-4 (FIB-4) assessment as the first line NIT. The model included treatment effects of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.”
> “All screening strategies for high-risk MASLD in US incurred additional costs compared to no screening, ranging from $13 587 to $14 730 per patient with T2D and $14 274 to $15 661 per patient with obesity.”
> “ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24  992 per QALY for patients with obesity. While ICERs were influenced by VCTE availability, they remained cost-effective when using ELF as the second-line test.”

Source: [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

<a id="topic-2.2.1.8.4-5"></a>

### Five-year direct costs of FIB-4 followed by ELF or VCTE screening of all US adults living with diabetes, 2026 to 2030, study funded by test and drug manufacturers

> “This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.”
> “The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment.”
> “Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US.”
> “Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.”
> “This study was funded by Boehringer Ingelheim, Echosens and Novo Nordisk.”

Source: [Lazarus et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12589856/)

<a id="topic-2.2.1.8.4-6"></a>

### Number of VCTE examinations needed under the current FIB-4-based algorithm for 75.8 million US adults with MASLD, NHANES 2017 to 2020

> “Current guidelines recommend using the Fibrosis-4 score for initial identification of subjects at risk of future complications.”
> “We interrogated the National Health and Nutrition Examination Survey data, 2017–20, in which a sample of subjects representative of US civilian population underwent vibration-controlled transient elastography (VCTE).”
> “In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa. When the current guideline was applied, 18.1 million VCTEs would be needed to diagnose 3.5 million subjects with LSM ≥8 kPa and 1.7 million subjects with LSM ≥12 kPa.”
> “would detect 4.9 million with LSM ≥8 kPa and 2.5 million subjects with LSM ≥12 kPa (37% and 45% improvement over the current guideline, respectively), while requiring 5.0 million fewer VCTEs (28% reduction).”

Source: [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/)

<a id="topic-2.2.1.8.4-7"></a>

### Confirmatory fibrosis testing needed after FIB-4 screening of 8,366 US primary care patients with type 2 diabetes or prediabetes, 2022 to 2024

> “This cross-sectional study evaluated primary care patients with T2DM or prediabetes and a FIB-4 score between 2022 and 2024.”
> “Of 8,366 patients with T2DM and prediabetes, 2,064 (25%) had FIB-4s in need of confirmatory risk assessment. The expanded FIB-4 fibrosis screening for T2DM and prediabetes increased the number of patients needing confirmatory fibrosis risk assessment by 9.1 times compared to those with diagnoses of MASLD (n=228).”
> “Expanded screening for advanced liver fibrosis would substantially increase the number of patients who need confirmatory testing for liver fibrosis, increasing cost and straining access.”
> “Second, we only included patients from a single academic healthcare system in the southeastern United States”

Source: [Patel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094816/)

<a id="topic-2.2.1.8.4-8"></a>

### Use of liver biopsy and transient elastography in US and European NASH practice, GAIN study

> “Key differences in practice between the EU5 countries and USA were that imaging techniques were less frequently used in the USA: 618 (51%) patients received an ultrasound compared with an average of 76% in EU5 countries; and only a minority received transient elastography: 157 (13%) compared with a total of 1,071 (42%) in EU5 countries.”
> “The reported rate of liver biopsy was lowest in Spain (130 patients, 25%), and highest in the USA (697, 57%).”
> “For instance, in the USA, the main sources of data were the Medicaid National Average Drug Acquisition Cost database for drug costs, the Centre for Medicare and Medicaid services for test procedures and surgeries, and the American Medical Association for consultations.”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.4-9"></a>

### Number of diagnostic tests and biopsy confirmation rate by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “However, only 22.9% (n = 532/2,319) of patients had their MASH diagnosis confirmed by liver biopsy. Non-invasive diagnostic techniques were reported for 97.3% of patients (n = 2,513/2,584).”
> “To diagnose MASH, a mean of 19.6 ± 11.29 tests were conducted in total. The most common test type was comorbidity assessments (5.5 ± 4.1). On average, significantly more diagnostic tests were required for patients with EFwC (19.7 ± 11.3, p = 0.0054) and AFwC (23.8 ± 11.9, p <0.0001) compared with those with EFnoC (17.4 ± 10.1).”
> “In addition, patients with AFwC required significantly more imaging scans to monitor MASH in the 2 years before data collection compared with those with EFnoC (p <0.0001).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
